Drug intelligence / Profile preview

Yajiafang

Development stage: Preclinical
Lead developer: Shanghai Sixth People’s Hospital
Administration: Oral

Overview

Yajiafang (亚甲方) is a Traditional Chinese Medicine (TCM) herbal formula developed by the Shanghai Sixth People's Hospital for the treatment of subacute granulomatous thyroiditis (also known as de Quervain's thyroiditis). In TCM theory, the formula is designed to address syndromes of excessive heat, toxin accumulation, blood heat, and blood stasis. It is typically administered as an oral decoction, often in conjunction with standard Western therapies like glucocorticoids, to enhance efficacy and reduce the risk of recurrence or steroid-related side effects. Clinical evaluation of the formula has been conducted through trials registered in the Chinese Clinical Trial Registry (ChiCTR), focusing on its ability to improve clinical symptoms and laboratory markers of inflammation.

Brand names: Yajiafang
Other names: Subparty A亚甲方

Beyond the preview

Go deeper on Yajiafang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yajiafang.

Explore the full profile